ArticleJTCVS structural and endovascular2026
Outcome of cerebral embolic protection during transcatheter aortic valve replacement in high-risk patient for stroke.
Article in JTCVS structural and endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The sentinel cerebral embolic protection device has been used as prophylaxis of stroke and transient ischemic attack during transcatheter aortic valve replacement. However, there are no absolute criteria guiding cerebral embolic protection device placement. This study aimed to evaluate the impact of cerebral embolic protection on postoperative cerebrovascular events in patients at high risk for stroke. Methods: Between April 2021 and August 2023, 695 patients underwent transcatheter aortic valve replacement through a transfemoral approach. The cerebral embolic protection device was placed at the beginning of transcatheter aortic valve replacement procedure when 1 of the following criteria was met preoperatively: bicuspid aortic valve, valve-in-valve procedure, or calcium score in computed tomography greater than 1000. Of 695 patients with transcatheter aortic valve replacement, 636 met the criteria. The cerebral embolic protection device was placed in 55% of patients (350/636, cerebral embolic protection group) and not placed in 45% of patients (286/636, non-cerebral embolic protection group) because cerebral embolic protection was not feasible anatomically. A 1:1 propensity score matching was performed using the nearest neighbor method between cerebral embolic protection and non-cerebral embolic protection groups. Results: A total of 245 pairs were matched in propensity score matching. After matching, postoperative stroke/transient ischemic attack occurred in 0.4% (1/245) in the cerebral embolic protection group and 2.9% (7/245) in the non-cerebral embolic protection group. A significant difference was noted in postoperative stroke/transient ischemic attack between the 2 groups ( Conclusions: Cerebral embolic protection during transcatheter aortic valve replacement might reduce postoperative cerebrovascular events in patients who are high risk for stroke in this patient cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.